Security
Lexeo Therapeutics, Inc. Common Stock · LXEO
LXEONASDAQCommon stockCurrentCIK 1907108Updated Nov 19, 2026
LXEO price & chart
Loading TradingView…
NASDAQ:LXEO on TradingView ↗About the company
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for PKP2-ACM, and others in devastating diseases with high unmet need.
In the news
Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference ↗
Recent filings
4 filing
3 filing
SCHEDULE 13G/A - filed by ORBIMED ADVISORS LLC regarding Lexeo Therapeutics, Inc.
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure · Other Events
Items 2.02, 7.01, 8.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 143,844,000Source | 173,865,000Source | 254,898,000Source | 176,068,000Source | 192,007,000Source | 250,356,000Source | 125,690,000Source | 213,205,000Source | 268,688,000Source | 146,942,000Source | 139,807,000Source | 97,076,000Source |
| Property, Plant and Equipment, NetUSD | 1,230,000Source | 1,180,000Source | 1,121,000Source | 1,115,000Source | 1,205,000Source | 1,101,000Source | 1,045,000Source | 1,044,000Source | 1,139,000Source | 1,028,000Source | 1,056,000Source | 998,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 40,996,000Source | 157,020,000Source | 92,834,000Source | 35,480,000Source | 174,981,000Source | 71,768,000Source | 28,913,000Source | 195,060,000Source | 63,000,000Source | 35,014,000Source | 121,466,000Source | 77,335,000Source |
| Assets, CurrentUSD | 127,793,000Source | 159,458,000Source | 217,908,000Source | 140,062,000Source | 177,149,000Source | 200,862,000Source | 105,274,000Source | 198,089,000Source | 188,392,000Source | 126,121,000Source | 124,294,000Source | 80,048,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,029,000Source | 2,438,000Source | 6,205,000Source | 7,169,000Source | 2,168,000Source | 7,819,000Source | 5,443,000Source | 3,029,000Source | 6,625,000Source | 4,603,000Source | — | — |
| Operating Lease, Right-of-Use AssetUSD | 6,963,000Source | 8,435,000Source | 5,783,000Source | 7,340,000Source | 8,781,000Source | 6,185,000Source | 7,708,000Source | 9,120,000Source | 6,578,000Source | 8,069,000Source | 9,442,000Source | 10,708,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 23,013,000Source | 34,539,000Source | 19,837,000Source | 37,850,000Source | 27,059,000Source | 18,859,000Source | 37,575,000Source | 30,255,000Source | 22,019,000Source | 30,100,000Source | 26,272,000Source | 24,997,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 5,000Source | 3,000Source | 8,000Source | 5,000Source | 3,000Source | 7,000Source | 3,000Source | 3,000Source | 7,000Source | 3,000Source | 3,000Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -359,215,000Source | -254,249,000Source | -426,197,000Source | -338,932,000Source | -224,760,000Source | -400,330,000Source | -312,829,000Source | -203,522,000Source | -380,134,000Source | -280,173,000Source | -181,840,000Source | -115,446,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 89,000Source | — | -298,000Source | -13,000Source | — | -142,000Source | -54,000Source | — | 188,000Source | -103,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 120,831,000Source | 139,326,000Source | 235,061,000Source | 138,218,000Source | 164,948,000Source | 231,497,000Source | 88,115,000Source | 182,950,000Source | 246,669,000Source | 116,842,000Source | 113,535,000Source | -112,954,000Source |
| Additional Paid in Capital, Common StockUSD | 479,969,000Source | 393,585,000Source | 661,565,000Source | 477,175,000Source | 389,718,000Source | 631,979,000Source | 401,012,000Source | 386,469,000Source | 626,625,000Source | 397,132,000Source | 295,372,000Source | 2,492,000Source |
| Liabilities and EquityUSD | 143,844,000Source | 173,865,000Source | 254,898,000Source | 176,068,000Source | 192,007,000Source | 250,356,000Source | 125,690,000Source | 213,205,000Source | 268,688,000Source | 146,942,000Source | 139,807,000Source | 97,076,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 17,271,000Source | 26,818,000Source | 15,692,000Source | 31,593,000Source | 18,877,000Source | 14,189,000Source | 30,823,000Source | 21,630,000Source | 16,808,000Source | 22,846,000Source | 17,239,000Source | 14,349,000Source |
| Operating Lease, Liability, CurrentUSD | 2,147,000Source | 2,108,000Source | 2,177,000Source | 2,136,000Source | 2,098,000Source | 2,167,000Source | 2,126,000Source | 2,087,000Source | 2,157,000Source | 2,100,000Source | 2,087,000Source | 2,287,000Source |
| Accounts Payable, CurrentUSD | 4,656,000Source | 8,438,000Source | 4,179,000Source | 20,025,000Source | 5,765,000Source | 3,335,000Source | 11,981,000Source | 4,297,000Source | 4,856,000Source | 6,417,000Source | 3,794,000Source | 2,678,000Source |
| Operating Lease, Liability, NoncurrentUSD | 5,288,000Source | 6,791,000Source | 4,050,000Source | 5,680,000Source | 7,139,000Source | 4,472,000Source | 6,054,000Source | 7,471,000Source | 4,884,000Source | 6,437,000Source | 7,786,000Source | 9,000,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 234,200,000Source | — | — | 227,600,000Source | 106,900,000Source | — | — | 128,500,000Source | — | — |
| Short-term InvestmentsUSD | — | — | — | — | — | — | 70,918,000Source | — | — | 86,504,000Source | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -20,196,000Source | -32,656,000Source | -99,961,000Source | -98,333,000Source | -66,394,000Source | -59,277,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,755,000Source | 3,697,000Source | 12,132,000Source | 12,474,000Source | 3,043,000Source | 1,781,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,596,000Source | 5,143,000Source | -1,561,000Source | 2,378,000Source | -180,000Source | -426,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -21,144,000Source | -21,716,000Source | -98,561,000Source | -81,151,000Source | -59,496,000Source | -54,560,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 27,460,000Source | 15,600,000Source | -90,252,000Source | -94,077,000Source | -165,000Source | -901,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 35,000Source | — | 397,000Source | 481,000Source | 115,000Source | 672,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 2,452,000Source | 11,000Source | 216,795,000Source | 88,776,000Source | 103,791,000Source | 189,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 8,768,000Source | -6,105,000Source | 27,982,000Source | -86,452,000Source | 44,130,000Source | -55,272,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 44,244,000Source | 160,272,000Source | 96,082,000Source | 38,728,000Source | 75,016,000Source | 32,161,000Source | 66,248,000Source | 38,266,000Source | 124,718,000Source | 80,588,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 104,000Source | 127,000Source | 176,000Source | 77,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 551,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,651,000Source | 3,790,000Source | 5,690,000Source | 3,071,000Source | 2,755,000Source | 3,697,000Source | 12,132,000Source | 12,474,000Source | 3,043,000Source | 1,781,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | 234,200,000Source | — | 227,600,000Source | 106,900,000Source | — | 128,500,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 5,953,000Source | 8,120,000Source | 8,993,000Source | 15,967,000Source | 6,630,000Source | 16,634,000Source | 45,460,000Source | 31,675,000Source | 15,383,000Source | 12,001,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| InterestExpenseNonoperatingUSD | — | — | 22,000Source | 35,000Source | 14,000Source | 25,000Source | 17,000Source | 28,000Source | 95,000Source | 137,000Source | — | — |
| Investment Income, InterestUSD | — | — | 1,456,000Source | 2,092,000Source | 2,194,000Source | 1,268,000Source | 2,113,000Source | 1,193,000Source | 6,130,000Source | 7,556,000Source | 2,867,000Source | 1,325,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -20,283,000Source | -29,489,000Source | -25,867,000Source | -26,103,000Source | -20,196,000Source | -32,656,000Source | -99,961,000Source | -98,333,000Source | -66,394,000Source | -59,277,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,365,000Source | 2,054,000Source | 2,153,000Source | 4,585,000Source | 2,137,000Source | 1,149,000Source | 9,296,000Source | 7,433,000Source | 2,119,000Source | 1,232,000Source |
| Operating ExpensesUSD | — | — | 21,648,000Source | 31,543,000Source | 28,020,000Source | 30,688,000Source | 22,333,000Source | 33,805,000Source | 109,257,000Source | 105,766,000Source | 68,513,000Source | 61,163,000Source |
| Operating Lease, ExpenseUSD | — | — | 667,000Source | 653,000Source | 665,000Source | 663,000Source | 668,000Source | 663,000Source | 2,650,000Source | 2,606,000Source | 2,502,000Source | 1,795,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -9,000Source | -3,000Source | -6,000Source | -14,000Source | -1,000Source | -4,000Source | -18,000Source | -9,000Source | -13,000Source | -2,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | 195,382,000Source | 93,596,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 143,000Source | 170,000Source | 270,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 9,000Source | — | 59,000Source | 491,000Source | 51,000Source | 332,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | 102,000Source | — | -156,000Source | 41,000Source | -330,000Source | 49,000Source | 291,000Source | -103,000Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | — | — | 654,000Source |
| Operating Income (Loss)USD | — | — | -21,648,000Source | -31,543,000Source | -28,020,000Source | -30,688,000Source | -22,333,000Source | -33,805,000Source | -109,257,000Source | -105,766,000Source | -68,513,000Source | -60,509,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -9,000Source | -3,000Source | -6,000Source | -14,000Source | -1,000Source | -4,000Source | -18,000Source | -9,000Source | -13,000Source | -2,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -20,283,000Source | -29,489,000Source | -25,867,000Source | -26,103,000Source | -20,196,000Source | -32,656,000Source | -99,670,000Source | -98,333,000Source | -66,394,000Source | -59,277,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -20,283,000Source | -29,489,000Source | -25,867,000Source | -26,103,000Source | -20,196,000Source | -32,656,000Source | -99,961,000Source | -98,333,000Source | -66,394,000Source | -59,277,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.33Source | -0.89Source | -0.3Source | -0.6Source | -0.25Source | -0.99Source | -1.86Source | -3.09Source | -12.4Source | -36.36Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.33Source | -0.89Source | -0.3Source | -0.6Source | -0.25Source | -0.99Source | -1.86Source | -3.09Source | -12.4Source | -36.36Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 60,980,867Source | 33,063,153Source | 85,626,751Source | 43,573,628Source | 81,183,812Source | 33,113,991Source | 53,645,323Source | 31,787,491Source | 5,354,368Source | 1,630,348Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 60,980,867Source | 33,063,153Source | 85,626,751Source | 43,573,628Source | 81,183,812Source | 33,113,991Source | 53,645,323Source | 31,787,491Source | 5,354,368Source | 1,630,348Source |
| Interest Expense (non-operating)USD | — | — | 22,000Source | 35,000Source | 14,000Source | 25,000Source | 17,000Source | 28,000Source | 95,000Source | 137,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 73,000Source | 60,000Source | 268,000Source | 304,000Source | 271,000Source | 120,000Source |
| General and Administrative ExpenseUSD | — | — | 5,953,000Source | 8,120,000Source | 8,993,000Source | 15,967,000Source | 6,630,000Source | 16,634,000Source | 45,460,000Source | 31,675,000Source | 15,383,000Source | 12,001,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -99,670,000Source | — | — | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 205,000Source | 91,000Source |
| Investment Income, InterestUSD | — | — | 1,456,000Source | 2,092,000Source | 2,194,000Source | 1,268,000Source | 2,113,000Source | 1,193,000Source | 6,130,000Source | 7,556,000Source | 2,867,000Source | 1,325,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,365,000Source | 2,054,000Source | 2,153,000Source | 4,585,000Source | 2,137,000Source | 1,149,000Source | 9,296,000Source | 7,433,000Source | 2,119,000Source | 1,232,000Source |
| Operating ExpensesUSD | — | — | 21,648,000Source | 31,543,000Source | 28,020,000Source | 30,688,000Source | 22,333,000Source | 33,805,000Source | 109,257,000Source | 105,766,000Source | 68,513,000Source | 61,163,000Source |
| Operating Lease, ExpenseUSD | — | — | 667,000Source | 653,000Source | 665,000Source | 663,000Source | 668,000Source | 663,000Source | 2,650,000Source | 2,606,000Source | 2,502,000Source | 1,795,000Source |
| Research and Development ExpenseUSD | — | — | 15,695,000Source | 23,423,000Source | 19,027,000Source | 14,721,000Source | 15,703,000Source | 17,171,000Source | 63,797,000Source | 74,091,000Source | 53,130,000Source | 49,162,000Source |
Offerings
Registration 333-299689
Filing attachments
lxeo-ex99_1.htm · 8-K · 2026-11-16
Exhibit 99.1 Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results Participants in high-dose cohorts achieved 80% mean reduction in non-sustained ventricular tachycardia and 44% mean reduction in premature ventricular contractions at latest assessment LX2020 generally well tolerated across 10 participants with no clinically significant complement activation U.S. Fo…
Read attachment ↗lxeo-ex99_2.htm · 8-K · 2026-11-16
Interim Clinical Data from the Phase 1/2 HEROIC-PKP2 Trial of LX2020 in PKP2 Arrhythmogenic Cardiomyopathy November 16, 2026 Exhibit 99.2 1 Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs, the anticipated benefits of its current product candidates, and the timing and likelihood of potential regu…
Read attachment ↗d238747dex43.htm · S-3 · 2026-10-29
Exhibit 4.3 LEXEO THERAPEUTICS, INC. INDENTURE Dated as of, 20 [__________] Trustee -1- TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Ru…
Read attachment ↗lxeo-ex99_1.htm · 8-K · 2026-09-22
Exhibit 99.1 Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia Acquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace frataxin in the brain Collaborations launched to evaluate gene therapy sequential dosing following treatment with LX2006 and explore cerebellar targeting to optimize outcomes in FA associated neurological disease SUNR…
Read attachment ↗lxeo-ex99_2.htm · 8-K · 2026-09-22
BusinessUpdate September 22, 2026 Exhibit 99.2 1 This presentation contains “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs, the anticipated benefits of its current product candidates, the timing for receipt and announcement of data from its clinical trials, the timing and likelihood of potential regulatory developments, trial design changes and ap…
Read attachment ↗lxeo-ex99_1.htm · 8-K · 2026-08-12
EX-99.1 2 lxeo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first patient enrolled into pivotal study in June; site activation efforts ongoing CLARITY-FA enrollment continues to advance, supporting identificati…
Read attachment ↗